SSA
CORT icon

Schonfeld Strategic Advisors’s Corcept Therapeutics CORT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$11.4K – 2107
2025
Q1 		$11.4K Buy
+100
New +$6.09K ﹤0.01% 2118
2024
Q3 		– Sell
-11,346
Closed -$369K – 2095
2024
Q2 		$369K Buy
+11,346
New +$311K ﹤0.01% 1603
2022
Q4 		– Sell
-37,068
Closed -$950K – 2651
2022
Q3 		$950K Buy
+37,068
New +$992K 0.01% 1303
2020
Q2 		– Sell
-15,162
Closed -$180K – 1283
2020
Q1 		$180K Buy
+15,162
New +$188K 0.01% 928
2017
Q2 		– Sell
-100,005
Closed -$1.1M – 633
2017
Q1 		$1.1M Sell
100,005
-198,984
-67% -$1.75M 0.11% 242
2016
Q4 		$2.17M Buy
+298,989
New +$2.34M 0.28% 103

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Schonfeld Strategic Advisors's CORT Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 100 shares — an estimated $11.4K sold.

Schonfeld Strategic Advisors first reported a position in CORT in Q4 2016 and held it in 6 quarters. The position peaked at $2.17M in Q4 2016. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 100 Corcept Therapeutics shares in Q2 2025, an estimated $11.4K.
  • Schonfeld Strategic Advisors first reported a position in Corcept Therapeutics in Q4 2016 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's Corcept Therapeutics position peaked at $2.17M in Q4 2016.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.